Nateglinide: A new member of the meglitinide family for postprandial glucose control in type 2 diabetes

Formulary

Volumn 35, Issue 10, 2000, Pages 798-811

  Schrand, L M ^a   Spanheimer, R G ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; NATEGLINIDE; REPAGLINIDE;

AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HEADACHE; HUMAN; HYPOGLYCEMIA; LIVER FUNCTION TEST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033783179     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults
2. Economic consequences of diabetes mellitus in the U.S. in 1997
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
5. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family
6. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells
7. Nateglinide: A glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas
8. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes
9. Synergistic effects of nateglinide meal administration on insulin secretion in patients with type 2 diabetes mellitus
10. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects
11. Pharmacodynamics of nateglinide and repaglinide in cynomolgus monkeys
12. Mimicking cephalic insulin release with the rapid onset/short duration insulinotropic agent, nateglinide, reduces prandial glucose excursions without increasing total insulin exposure in IGT monkeys
13. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl-cycloheanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide
14. Effects of AY-4166 on pancreatic A- and B- cells: Comparative study with glibenclamide in isolated perfused rat pancreas
15. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin
16. The hypoglycaemic properties of a novel phenylalanine derivative in healthy subjects - Timing of administration and meal effect on absorption
17. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus
18. Nateglinide (A-4166), a new insulinotropic agent, controls prandial hyperglycemia in type 2 diabetic patients
19. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
20. Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure
21. Reduced postprandial hyperglycemia by A-4166 compared to voglibose in NIDDM subjects in Japan
22. Comparison of mealtime glucose regulation by nateglinide repaglinide in healthy subjects
23. Nateglinide improves glycemic control alone and in combination with troglitazone in patients with type 2 diabetes
24. Nateglinide alone and in combination with metformin improves glycemic control be reducing-mealtime glucose spikes in type 2 diabetes
25. Nateglinide added to metformin offers safe and effective treatment for type 2 diabetes
26. Update: Clinically significant cytochrome P-450 drug interactions